Previous 10 | Next 10 |
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +155%, Edesa Biotech (NASDAQ:EDSA) +34%, Atea Pharmaceuticals (NASDAQ:AVIR) +20%, Synlogic (NASDAQ:SYBX) +13%, Viveve Medical (NASDAQ:VIVE) +9%. Losers: BeyondSpring (NASDAQ:BYSI) -22%, Protagonist Therap...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the term “technology” often brings to mind the broader digitalization movement, tech actually has the most potential in healthcare. Thanks to groundbreaking innovations, we now know much more about the h...
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea mana...
In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752 Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 400 million infections each year global...
Image source: The Motley Fool. Atea Pharmaceuticals Inc (NASDAQ: AVIR) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Atea Pharmaceuticals Inc (AVIR) Q2 2021 Earnings Call Transcript ...
Atea Pharmaceuticals, Inc. (AVIR) Q2 2021 Earnings Conference Call August 12, 2021 04:30 PM ET Company Participants Jonae Barnes - SVP, Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and CEO Janet Hammond - Chief Development Officer Andrea Corcoran ...
The following slide deck was published by Atea Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Atea Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
New Data in Healthy Volunteers Confirmed that AT-527’s Active Metabolite Achieved Target Antiviral Levels in Lungs, Key Site of COVID-19 Infection AT-527 Phase 2 Study Interim Results Showed Potent and Rapid Antiviral Activity in Hospitalized Patients; Study to Advanc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After most of 2020 went down the drain in terms of planned events and even mundane social activities, few want to discuss the novel coronavirus pandemic. As a Bloomberg article published earlier this year reported, retail...
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...